No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ACRE240517P10000
- 3.30
- 0.000.00%
15min DelayClose May 13 16:00 ET
3.30High3.30Low
3.30Open3.30Pre Close1 Volume133 Open Interest10.00Strike Price330.00Turnover266.26%IV-1.19%PremiumMay 17, 2024Expiry Date3.27Intrinsic Value100Multiplier4DDays to Expiry0.03Time Value100Contract SizeAmericanOptions Type-0.8958Delta0.0957Gamma2.01Leverage Ratio-0.0376Theta-0.0009Rho-1.80Eff Leverage0.0013Vega
Intraday
- 5D
- 1D
News
Ares Commercial Real Estate Corporation (NYSE:ACRE) Q1 2024 Earnings Call Transcript
Ares Commercial Real Est Is Maintained at Market Perform by Keefe, Bruyette & Woods
Ares Commercial Real Est Is Maintained at Market Perform by Keefe, Bruyette & Woods
Express News | Keefe, Bruyette & Woods Maintains Market Perform on Ares Comml Real Est, Lowers Price Target to $7
Ares Comml Real Est Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 4.48% Keefe, Bruyette & Woods $7.5 → $7 Maintains Market Perform 04/10/2024 11.94% Keefe, Bruye
Ares Commercial Real Estate Corp.: Hold Rating Maintained Amidst Financial Uncertainties and Dividend Stability
Q1 2024 Ares Commercial Real Estate Corp Earnings Call
Comments
Despite Ares Commercial Real Estate's declining EPS and share price, market optimism suggests potential investment opportunities. However, 5 warning signs in investment analysis, including 2 significant ones, could be concerning.
Pulling Back 11% This Week, Ares Commercial Real Estate's NYSE:ACRE) Five-year Decline in Earnings May Be Coming Into Investors FocusThe JMP analyst advises a cautious stance on ACRE amid current challenges, insisting on monitoring credit resolutions and new problem credits to gain confidence in future book value per share.
Gainers:
• $Cytokinetics(CYTK.US$ +8.7% (prices offering of of $450.0 mln of 3.50% convertible senior notes due 2027)
• $XPeng(XPEV.US$ +3.4% (June deliveries)
• $NIO Inc(NIO.US$ +2.9% (June deliveries)
• $Bitfarms(BITF.US$ +2.7% (provides June 2022 production and mining operations update)
• $Accolade(ACCD.US$ +2.7% (In reaction to earnings/guidance)
• $BioCryst Pharmaceuticals(BCRX.US$ +2.6% (presents new data demonstrating...
• $Cytokinetics(CYTK.US$ +8.7% (prices offering of of $450.0 mln of 3.50% convertible senior notes due 2027)
• $XPeng(XPEV.US$ +3.4% (June deliveries)
• $NIO Inc(NIO.US$ +2.9% (June deliveries)
• $Bitfarms(BITF.US$ +2.7% (provides June 2022 production and mining operations update)
• $Accolade(ACCD.US$ +2.7% (In reaction to earnings/guidance)
• $BioCryst Pharmaceuticals(BCRX.US$ +2.6% (presents new data demonstrating...
18
1
Gainers:
• $National CineMedia(NCMI.US$ +17.9% (AMC discloses 6.8% stake in NCMI)
• $MagnaChip Semiconductor(MX.US$ +14.8% (report that private equity firms including Carlyle Group (CG) will bid for the company)
• $DLocal(DLO.US$ +13.7% (In reaction to earnings)
• $SiriusPoint(SPNT.US$ +8.2% (Chairman and CEO resigns to pursue other opportunities)
• $Beyond Air(XAIR.US$ +6.4% (presents positive study update from the at-home LungF...
• $National CineMedia(NCMI.US$ +17.9% (AMC discloses 6.8% stake in NCMI)
• $MagnaChip Semiconductor(MX.US$ +14.8% (report that private equity firms including Carlyle Group (CG) will bid for the company)
• $DLocal(DLO.US$ +13.7% (In reaction to earnings)
• $SiriusPoint(SPNT.US$ +8.2% (Chairman and CEO resigns to pursue other opportunities)
• $Beyond Air(XAIR.US$ +6.4% (presents positive study update from the at-home LungF...
14
1
Read more